%0 Journal Article
%T Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment
%A James G. Krueger
%A Jason E. Hawkes
%A Tom C. Chan
%J Archive of "Therapeutic Advances in Chronic Disease".
%D 2018
%R 10.1177/2040622318759282
%X Plaque psoriasis is one of the most common autoimmune skin diseases and is characterized by erythematous, scaly plaques. Many highly effective, targeted therapies have been developed as a result of an improved understanding of the pathogenesis of psoriasis. Using agents that target the central interleukin (IL)-23/IL-17 immune axis, this once difficult-to-treat disease is now among the most effectively treated autoimmune diseases with major clinical improvements possible in around 90% of patients. In this article, we outline the immune mechanisms responsible for the development of psoriasis and provide an overview of the novel IL-23 antagonists being used to manage this chronic skin disease
%K guselkumab
%K interleukin 17
%K interleukin 23
%K mirikizumab
%K psoriasis
%K risankizumab
%K tildrakizumab
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956648/